Pubblicazioni

A clinical evaluation of monoclonal (CA19-9, CA50, CA12-5) and polyclonal (CEA, TPA) antibody-defined antigens for the diagnosis of pancreatic cancer  (1988)

Autori:
L. Benini; G. Cavallini; D. Zordan; P. Rizzotti; L. Rigo; G. Brocco; L. Perobelli; M. Zanchetta; P. Pederzoli; L. A. Scuro
Titolo:
A clinical evaluation of monoclonal (CA19-9, CA50, CA12-5) and polyclonal (CEA, TPA) antibody-defined antigens for the diagnosis of pancreatic cancer
Anno:
1988
Tipologia prodotto:
Articolo in Rivista
Tipologia ANVUR:
Articolo su rivista
Nazioni degli autori:
ITALIA
Lingua:
Inglese
Formato:
A Stampa
Referee:
Nome rivista:
Pancreas
ISSN Rivista:
0885-3177
N° Volume:
3
Intervallo pagine:
61-66
Parole chiave:
pancreatic cancer, diagnosis, Ca 19-9, pancreatic diseases
Breve descrizione dei contenuti:
We measured in 193 patients, admitted to our wards for symptoms and signs suggestive of pancreatic or digestive malignancy, the serum levels of five tumor-associated antigens (CA 19-9, CA 50, CA 125, TPA, CEA) and we evaluated their diagnostic accuracy both when used alone and in combination. For CA 19-9 and CA 50 a sensitivity for pancreatic cancer as high as 92 and 88%, respectively, and specificity of 91.8% were found. A lower sensitivity vs. pancreatic cancer was found for the other tumor markers, and vs. the other digestive and nondigestive malignancies for all tumor markers (apart for CA 19-9 and CA 50 vs. biliary carcinomas). As for the combined assays, the best figures were found vs. pancreatic cancer for CA 19-9 plus CA 50, CA 50 plus CEA, CA 50 plus CA 125; a sensitivity by far worse vs. the other gastrointestinal cancers was found for all the possible combinations. We conclude that in selected symptomatic patients some tumor-marker determinations can be useful in identifying those with a high probability of harboring a pancreatic cancer, to be further studied or operated upon. The clinical relevance of this in patients already symptomatic is at present unclear.
Id prodotto:
1208
Handle IRIS:
11562/1208
depositato il:
11 luglio 2012
ultima modifica:
2 novembre 2016
Citazione bibliografica:
L. Benini; G. Cavallini; D. Zordan; P. Rizzotti; L. Rigo; G. Brocco; L. Perobelli; M. Zanchetta; P. Pederzoli; L. A. Scuro, A clinical evaluation of monoclonal (CA19-9, CA50, CA12-5) and polyclonal (CEA, TPA) antibody-defined antigens for the diagnosis of pancreatic cancer «Pancreas» , vol. 31988pp. 61-66

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo IRIS

<<indietro

Attività

Strutture

Condividi